Improving pertussis vaccination

Berbers, Guy A. M.; Greeff, Sabine C. de; Mooi, Frits R.

doi:10.4161/hv.8112

Cited by 55 publications

(52 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For the neutralization assay, antibodies were expressed as recombinant scAbs, composed of the variable light chain (V L ) joined to a flexible (Gly 4 Ser) 2 linker and the variable heavy chain (V H ), followed by a C-terminal human chain constant region to increase solubility and serve as a detection handle (9). Based on multiple sequence alignments, 31 antibodies with unique complementary determining regions were selected for scAb expression (Fig.…”

Section: Volume 290 • Number 6 • February 6 2015mentioning

confidence: 99%

“…Exciting approaches in development to enhance vaccinemediated protective immunity include a genetically attenuated B. pertussis for intranasal delivery (6), nanoparticle formulations, including purified antigens and novel adjuvant formulations (7), as well as inclusion of additional highly conserved antigens in the current vaccine (8,9). A strong candidate for inclusion in any of these is the adenylate cyclase toxin (ACT), 2 which aids in immune evasion and is produced by three closely related Bordetella species, including B. pertussis, Bordetella parapertussis, and Bordetella bronchiseptica (10,11).…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Bordetella Adenylate Cyclase Repeat-in-Toxin (RTX) Domain Is Immunodominant and Elicits Neutralizing Antibodies

Wang¹,

Maynard

2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

Section: Volume 290 • Number 6 • February 6 2015mentioning

confidence: 99%

mentioning

confidence: 99%

The Bordetella Adenylate Cyclase Repeat-in-Toxin (RTX) Domain Is Immunodominant and Elicits Neutralizing Antibodies

Wang¹,

Maynard

2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

“…A rise in non-vaccine alleles coincident with widespread vaccination has been documented for Bordetella pertussis (Elomaa et al 2005;Van Amersfoorth et al 2005;Van Gent et al 2009) leading some authors to propose that vaccine-driven epitope-evolution in B. pertussis is one factor-among several others (Berbers et al 2009)-that may contribute to whooping cough re-emergence in humans (Mooi et al 2001). However, it is not clear how Bordetella parapertussis-the other major aetiological agent of human whooping cough-might respond to the selective pressure exerted by large-scale pertussis vaccination.…”

Section: Introductionmentioning

confidence: 99%

Acellular pertussis vaccination facilitatesBordetella parapertussisinfection in a rodent model of bordetellosis

et al. 2010

View full text Add to dashboard Cite

Despite over 50 years of population-wide vaccination, whooping cough incidence is on the rise. Although Bordetella pertussis is considered the main causative agent of whooping cough in humans, Bordetella parapertussis infections are not uncommon. The widely used acellular whooping cough vaccines (aP) are comprised solely of B. pertussis antigens that hold little or no efficacy against B. parapertussis. Here, we ask how aP vaccination affects competitive interactions between Bordetella species within co-infected rodent hosts and thus the aP-driven strength and direction of in-host selection. We show that aP vaccination helped clear B. pertussis but resulted in an approximately 40-fold increase in B. parapertussis lung colony-forming units (CFUs). Such vaccine-mediated facilitation of B. parapertussis did not arise as a result of competitive release; B. parapertussis CFUs were higher in aP-relative to sham-vaccinated hosts regardless of whether infections were single or mixed. Further, we show that aP vaccination impedes host immunity against B. parapertussis-measured as reduced lung inflammatory and neutrophil responses. Thus, we conclude that aP vaccination interferes with the optimal clearance of B. parapertussis and enhances the performance of this pathogen. Our data raise the possibility that widespread aP vaccination can create hosts more susceptible to B. parapertussis infection.

show abstract

“…35 Reviews describing the concentrations of the different potential protective antigens in different vaccines in the marketplace, suboptimal vaccines and potential reasons for waning immunity was published recently. 35,99 Although the duration of immunity imparted by both the wP or aP has been claimed not appear to differ markedly, 100,101 of particular concern has been the recent upward trend in the global incidence of pertussis with a six-fold increase in reported cases over the last two decades. 16,102,103 The fact that young adults (vaccinated during their childhood) with none or waning immunity against whooping cough may serve as a reservoir for the pathogen and pass it on to their children, 16 has stimulated interest in the development of an alternative vaccine which can also be used safely in the adolescent and adult populations.…”

Section: 119mentioning

confidence: 99%

“…Although the effectiveness of this vaccine [dTap] in reducing the transmission of pertussis to children is not known, in a clinical trial the vaccine efficacy of the DTwP for transmission of infection to children vaccinated with three doses of the whole cell vaccine was 85% in comparison with 6%, for the DTaP vaccine indicating the ineffectiveness of the latter. 105 Evaluation of the "cocooning" strategy 7,99 in which parents and carers of the newborns are recommended to receive dTap vaccine around the time of the birth may help clarify the effectiveness of this approach in reducing pertussis transmission to vulnerable infants.…”

Section: 119mentioning

confidence: 99%